FDA Follow-On Biologics Guidance Will Have Broad Scope, But Not "Break New Ground"
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting CDER Director Galson says draft guidance will be out this spring. Scientific principles will cover range of biologics therapies – but scientific and legal obstacles will limit impact to a relative handful of products.